Fig. 1.

Kaplan–Meier analysis of progression-free survival. a all patients: median PFS in LDMC and CCT: 12.0 weeks vs. 12.0 weeks, Log-rank: p = 0.218. b younger patients: median PFS in LDMC and CCT: 15.0 weeks vs. 14.0 weeks, Log-rank: p = 0.212. c non-heavily pretreated patients: median PFS in LDMC and CCT: 17.0 weeks vs. 15.0 weeks, Log-rank: p = 0.531. d patients without multiple metastases: median PFS in LDMC and CCT: 16.0 weeks vs. 12.0 weeks, Log-rank: p = 0.064. e HR-positive patients: median PFS in LDMC and CCT: 12.0 weeks vs. 14.0 weeks, Log-rank: p = 0.570. f triple-negative patients: median PFS in LDMC and CCT: 12.0 weeks vs. 12.0 weeks, Log-rank: p = 0.081. LDMC low-dose metronomic chemotherapy), CCT conventional chemotherapy